Why this ASX 200 rocket stock is crashing again today

Investors are selling 4DMedical after a massive run.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

4DMedical Ltd (ASX: 4DX) shares are being sold off again on Thursday as investors take another look at one of the ASX's hottest stocks.

At the time of writing, the 4DMedical share price is down a sizeable 10.39% to $3.405.

That puts the stock down around 40% over the past month. It also leaves the share price more than 50% below its recent high of $7.37, which was reached on 14 April.

While the move is not being driven by any new announcements today, the sell-off appears tied to weaker momentum after a huge recent run.

Here's what investors are looking at.

White declining arrow on a blue graph with an animated man representing a falling share price.

Image source: Getty Images

A huge rally is now unwinding

This pullback follows a massive run in the share price.

Even after the recent drop, 4DMedical shares are still up around 1,040% since this time last year.

The stock has been helped by a string of updates over the past 12 months. These include regulatory progress, commercial agreements, and stronger interest in the company's lung imaging technology.

Its CT:VQ platform uses existing CT scans to create detailed maps of lung ventilation and blood flow. 4DMedical has previously highlighted US clearance, UK certification, and a commercial contract with GlaxoSmithKline as key steps.

That run helped send the share price to an all-time high in April.

Since then, investors appear to have been locking in gains as sentiment has cooled.

The stock has recorded several heavy down days, falling 5.47% yesterday and more than 20% over the past week.

The chart looks under pressure

The technical picture has also weakened.

The stock has broken well below its recent highs and is now trading near the bottom end of its recent range. The overall trend since mid-April has been lower, with each bounce struggling to hold.

The relative strength index (RSI) is sitting around 29, which puts the stock close to oversold territory. Meanwhile, the Bollinger Bands show the share price trading near the lower end of its recent range.

The lower band is sitting around $2.75, while the upper band is above $5.

From here, the first support area looks to be around $3.30, near the recent intraday low. If that breaks, the next level to watch could be closer to the lower Bollinger Band near $2.75.

Foolish Takeaway

I can see why investors are taking some money off the table after such a big run.

4DMedical has clear commercial progress, but the stock has raced a long way ahead of current earnings.

Personally, I would not be chasing this sell-off today. I would want to see the share price settle first, especially around the $3.30 support area.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended GSK. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A doctor appears shocked as he looks through binoculars on a blue background.
Healthcare Shares

Is this ASX healthcare share a buy for its 6.2% dividend yield?

Can this excellent ASX share deliver healthy cash payments?

Read more »

medical asx share price represented by doctor giving thumbs up
Healthcare Shares

3 compelling reasons to buy CSL shares today

A leading fund manager forecasts a looming rebound for CSL shares. But why?

Read more »

A doctor shrugs and holds his hands out.
Healthcare Shares

CSL shares hit a 9-year low, time to buy or stay away?

Writing off CSL entirely might be premature - or is it?

Read more »

A group of medical researchers stands side by side with each other wearing white coats in their research laboratory with scientific equipment in the background.
Healthcare Shares

Neuren Pharmaceuticals Q1 2026: DAYBUE sales soar

Neuren Pharmaceuticals posted a strong Q1 2026, with DAYBUE net sales and royalty income both rising more than 20% year-on-year.

Read more »

A man wakes up happy with a smile on his face and arms outstretched.
Healthcare Shares

3 reasons to buy this $42 billion ASX healthcare share

This one is for investors seeking quality, global reach, and durable earnings.

Read more »

Strong woman overlooking city.
Healthcare Shares

Down over 50%: Are CSL and Cochlear strong buys in May?

These ASX healthcare shares have disappointed investors, but their long-term growth stories may still be intact.

Read more »

Health workers shake hands and congratulate each other on good news.
Healthcare Shares

4 ASX healthcare shares to buy as sector struggles: experts

Some brokers see the healthcare sector's downward spiral as a buying opportunity.

Read more »

Cybersecurity professional man inspects server room and works on iPad.
Healthcare Shares

ALS reports cyber security incident impacting operations

ALS discloses a cyber security breach affecting operations; most systems are restored as investigations continue.

Read more »